Am J Gastroenterol 2021 May 4. Epub 2021 May 4.
Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Department of Internal Medicine IV, Jena University Hospital, Friedrich Schiller University, Jena, Germany; Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece; Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium; Arizona State University, Phoenix, Arizona, USA; Liver Unit, Hospital Cli[Combining Acute Accent]nic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain; Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy; Department of Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Introduction: Comparative data on scores that predict outcome in primary biliary cholangitis (PBC) are scarce. We aimed to assess and compare the prognostic value of the Mayo Risk Score (MRS, 1989 and 1994), UK-PBC score, and GLOBE score in a large international cohort of patients with PBC.
Methods: Ursodeoxycholic acid-treated patients from 7 centers participating in the GLOBAL PBC Study Group were included. Read More